CAS: 578-68-7; 4-Aminoquinoline

该化合物是一种有机化合物,其特征为肾脏结构,其四位位置为氨基氨基磺基,其表面是黄色至褐色的固体,以芳香特性著称,4-氨基尼的分子分子式为C9H8N2,其分子重量约为160.17克/摩尔,该化合物在乙醇和二甲基硫氧化物等有机溶剂中溶解,但在水中溶液有限.4-安米诺基尼对医药化学很感兴趣,因为它在抗疟和抗微生物剂的开发中具有潜在应用作用,允许进行各种化学修改,从而能够加强其生物活动.此外,它可以参与各种化学反应,包括电子替代和混合反应,使其成为有机合成的多用途中间体.然而,在处理该化合物时,应当采取安全防范措施,因为它可能构成健康风险,包括潜在的毒性.

结构式图片

相似化合物

3741-15-9 611-34-7 580-19-8

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号56-57-5 4-硝基喹啉-N-氧化物 | CAS号611-35-8 4-氯喹啉 | CAS号14164-96-6 allyl-quinolin-... | CAS号1198-40-9 4-氨基-7-氯喹啉 | CAS号872-50-4 N-甲基吡咯烷酮(NMP) | CAS号611-36-9 4-羟基喹啉 | CAS号7462-74-0 2-溴异丁酰胺 | CAS号3964-04-3 4-溴喹啉 | CAS号88518-80-3 N-hydroxyquinol... | CAS号16560-43-3 4-碘喹啉 | CAS号394-70-7 4-氟喹啉 | CAS号36825-36-2 4-氨基-3-溴喹啉 | CAS号3964-04-3 4-溴喹啉 | CAS号611-35-8 4-氯喹啉 | CAS号5332-24-1 3-溴喹啉 | CAS号529-37-3 喹啉-4(1H)-酮 | CAS号2508-86-3 4-aminoquinolin... | CAS号13720-91-7 4-乙氧基喹啉 | CAS号90224-83-2 3-溴-6-硝基喹啉-4-胺 | CAS号40107-09-3 4,6-喹啉二胺

合成工艺路线路线简述

    4-氯喹啉置于4,4'-二甲基-2,2'-联吡啶,Nickel Diacetate,溴化铵,1,8-二氮杂双环[5.4.0]十一碳-7-烯体系中,用 四氢呋喃,二甲基亚砜 作为反应溶剂,以82 %的收率获得产物4-氨基喹啉
    参考文献:Ni 催化芳基卤化物与铵盐偶联光化学合成苯胺
    标题:Ni 催化芳基卤化物与铵盐偶联光化学合成苯胺
    摘要:简单,高效和经济地合成苯胺仍然是合成化学中的一个重要挑战.在这项研究中,Ni(Oac) 2-联吡啶络合物表明在光的直接激发下很容易催化芳基卤化物与铵盐的胺化反应,从而使多种芳基氯和溴转化为相应的伯(杂) 在没有外部光敏剂的情况下的芳基胺.药物分子的后期修饰和伯芳基胺的15 N-标记也通过许多示例进行了演示.光诱导产生 Ni(I)-联吡啶物种被认为是反应中的关键步骤,使 Ni(I)/ni(Iii) 循环能够进行催化转换.
    DOI:10.1021/acscatal.2C04959

    海关参考信息

    专利信息


    专利号:WO-2013138200-A1
    优先权日:2012-03-13
    标 题 :Green chemistry synthesis of the malaria drug amodiaquine and analogs thereof
    发明人:FORTUNAK JOSEPH MARIAN; KULKARNI AMOL ANANT; KING CHRISTOPHER
    权利人:UNIV HOWARD
    摘要:Methods are provided for a green chemistry one-pot synthesis of amodiaquine and amodiaquine analogs. The methods have a lower environmental impact, lower investment cost, reduced amounts of byproducts and impurities, and a shorter synthesis time, compared to current conventional synthesis methods. The methods reduce the total number of steps in the synthesis from four to five down to two, thereby simplifying production; and allow a reduced number of solvents and reagents to be used in production, thereby reducing the waste generated in the synthesis. The methods can reduce the waste to about 3-5 kilograms of waste generated per kilogram of product produced; and surprisingly improve the overall yield from 60-65% to greater than 90% as compared to the current conventional synthesis methods for amodiaquine and its analogs.

    专利号:US-8497375-B2
    优先权日:2010-06-11
    标 题 :Method of synthesis of ferroquine by convergent reductive amination
    发明人:FEREY VINCENT; MATEOS-CARO JULIA; MONDIERE REGIS; VAYRON PHILIPPE; VIGNE SYLVIE
    权利人:SANOFI SA
    摘要:The invention relates to a method of synthesis of ferroquine of formula (F) or of its metabolite of formula (Fm): n n n n n n n n n n n n comprising a reaction of reductive amination, said reaction comprising: n (i) a stage of condensation of an aldehyde-amino ferrocene of formula (III), in which R represents a hydrogen atom or a methyl group, with 7-chloroquinolin-4-amine as shown below, n n n n n n n n n n n n n n n n followed by n (ii) a stage of reduction of the product of condensation obtained in the preceding stage and n (iii) then a stage of hydrolysis of the reaction mixture in the presence of an aqueous solution of ammonia or of citric acid.

    专利号:US-7211590-B2
    优先权日:2002-08-01
    标 题:Nitrosated proton pump inhibitors, compositions and methods of use
    发明人:FANG XINQIN; GARVEY DAVID S; LETTS L GORDON
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-9409879-B2
    优先权日:2011-03-29
    标 题 :Total synthesis of redox-active 1.4-naphthoquinones and their metabolites and their therapeutic use as antimalarial and schistomicidal agents
    发明人:DAVIOUD-CHARVET ELISABETH; LANFRANCHI DON ANTOINE; JOHANN LAURE; WILLIAMS DAVID LEE; CESAR RODO ELENA
    权利人:DAVIOUD-CHARVET ELISABETH; LANFRANCHI DON ANTOINE; JOHANN LAURE; WILLIAMS DAVID LEE; CESAR RODO ELENA; CENTRE NAT RECH SCIENT
    摘要:Naphthoquinones, azanaphthoquinones and benxanthones, their process of synthesis and methods of their use as antimalarial or antischistosomal agents.

    专利号:US-7947701-B2
    优先权日:2003-11-14
    标题:Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
    发明人:CAZELLES JEROME; COSLEDAN FREDERIC; MEUNIER BERNARD; PELLET ALAIN
    权利人:SANOFI AVENTIS
    摘要:The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.
    湖南华腾制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.huatengsci.com
    电话: 400-8592883 15367835770👤
    📞湖南华腾制药有限公司 ⚠️参考联系方式

    销售电话:400-8592883 15367835770
    邮箱:sales@huatengsci.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1186/1475-2875-9-53
    摘要:Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, Okuboyejo TM, Michael OS. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malaria Journal. 2010 Feb 15;9(1):53. doi: 10.1186/1475-2875-9-53.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知